NASDAQ · ALVOW
Healthcare · Drug Manufacturers - Specialty & Generic
$0.14
Down-$0.01 (-6.73%)
Updated Nov 5, 2026, 6:27 PM
SID Score
3.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ALVOW
1M range · 8 trading sessions · Daily adjusted prices
Prices through Nov 4, 2026
ALVOW closed at $0.14 after 8 trading sessions, down 66.67% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 4, 2026 | $0.1651 | $0.2101 | $0.14 | $0.14 | 12.2K |
| Nov 3, 2026 | $0.1801 | $0.24 | $0.1501 | $0.1501 | 10.11K |
| Nov 2, 2026 | $0.2951 | $0.2951 | $0.2951 | $0.2951 | 354 |
| Oct 30, 2026 | $0.4499 | $0.4499 | $0.2436 | $0.2436 | 2.29K |
| Oct 28, 2026 | $0.22 | $0.4027 | $0.17 | $0.1865 | 15.73K |
| Oct 27, 2026 | $0.1995 | $0.1995 | $0.1533 | $0.17 | 1.67K |
| Oct 26, 2026 | $0.1999 | $0.20 | $0.1999 | $0.1999 | 1.81K |
| Oct 23, 2026 | $0.4499 | $0.4499 | $0.42 | $0.42 | 1.18K |
The latest Smart Investors Daily articles mentioning ALVOW.
Company
Market Activity
Research & News
ALVOW research
Company profile and research snapshot.
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Yahoo · Oct 20, 2026
Investing.com -- Alvotech shares rose more than 6% in premarket trading Tuesday after the U.S. Food and Drug Administration approved a new manufacturing process for Simlandi, the company’s biosimilar to Humira.
Yahoo · Oct 20, 2026
Enhanced process increases manufacturing productivity and frees up capacity to support growing demand across Alvotech’s biosimilars portfolioREYKJAVIK, Iceland and LONDON, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has approved a new manufacturing process for SIMLANDI® (adalimumab-
Yahoo · Oct 16, 2026
Alvotech and Advanz Pharma previously submitted a European regulatory application for AVT29, a proposed biosimilar to Eylea 8 mg, as a line extension to the approved Mynzepli marketing authorization. This marked the first reported global filing targeting the higher dose aflibercept formulation. The move shifts Alvotech’s eye care portfolio toward the 8 mg Eylea segment, which recently represented about 57% of combined global Eylea 2 mg and 8 mg sales by value. This points to a focus on...
Yahoo · Oct 14, 2026
AVT29 submitted to the European Medicines Agency as a line extension to the existing marketing authorization for Mynzepli® (aflibercept 2 mg) High-dose aflibercept offers the potential to reduce treatment frequency for patients with retinal diseases REYKJAVIK, Iceland and LONDON, UK (October 14, 2026) - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Advanz Pharma Holdco Limited
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ALVOW.
